2011
DOI: 10.3111/13696998.2011.631067 View full text |Buy / Rent full text
|
|

Abstract: Results demonstrate that azacitidine provides greater clinical benefit and costs less than decitabine across all key outcomes. These results accentuate the positive role of azacitidine in providing cost-effective care for MDS.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
21
0

Publication Types

Select...

Relationship

0
0

Authors

Journals